Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus

Kim, Sun-Young; Jo, Dae-Sun; Hwang, Pyoung Han; Park, Ji Hyun; Park, Sung Kwang; Yi, Ho Keun; Lee, Dae-Yeol

doi:10.1016/j.metabol.2005.09.011

« Previous Next »Metabolism - Clinical and Experimental
Volume 55, Issue 3 , Pages 366-370, March 2006

Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus

Sun-Young Kim
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
- Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
Dae-Sun Jo
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
Pyoung Han Hwang
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
Ji Hyun Park
- Internal Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
Sung Kwang Park
- Renal Regeneration Laboratory, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
Ho Keun Yi
- Department of Biochemistry, School of Dentistry, Chonbuk National University, Jeonju, Korea
Dae-Yeol Lee
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
- Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-712, Korea
- Corresponding author. Department of Pediatrics, Chonbuk National University Hospital, Keumam-dong, Jeonju, Jeonbuk 561-712, Korea. Tel.: +82 63 250 1469; fax: +82 63 250 1464.

Received 22 April 2005; accepted 22 September 2005.

Abstract

Ghrelin is a novel gut-brain peptide, which exerts somatotropic, orexigenic, and adipogenic effects. Genetic variants of ghrelin have been associated with both obesity and insulin metabolism. In this study, we determined a role of preproghrelin Leu72Met polymorphism on type 2 diabetes mellitus and its relationship to variables studied. Genotypes were assessed by polymerase chain reaction. Frequencies of the Leu72Met polymorphism were found to be 35.4% in the type 2 diabetic patients and 32.5% in the normal controls. The Leu72Met polymorphism was not associated with hypertension, macroangiopathy, retinopathy, serum cholesterol, triglyceride, blood urea nitrogen, HbA_1c, lipoprotein (a), fasting insulin, or 24-hour urinary protein levels in the type 2 diabetic group. However, the Leu72Met polymorphism was clearly associated with serum creatinine levels in the diabetic group, as the Met72 carriers exhibited lower serum creatinine levels than the Met72 noncarriers. Our data indicate that the preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. However, the Leu72Met polymorphism is associated with serum creatinine levels. These data suggest that Met72 carrier status may be a predictable marker for diabetic nephropathy or renal impairment in type 2 diabetes mellitus.